PONV (Post-Operative Nausea and Vomiting) Adult and Review    body {font-family: 'Open Sans', sans-serif;}

### PONV (Post-Operative Nausea and Vomiting) Adult and Review

**PONV facts:  
**\- PONV is the second most common complaint, with pain being the most common.  
\- Uncontrolled PONV will prevent a patient from being discharged postoperatively.  
\- PONV has a multifactorial origin, such as patient-related risk factors.  
\- In anesthesia, it is common to administer ≥1 antiemetic on low-risk patients and ≥ 2 antiemetics for higher-risk patients.  
\- Using two or more different antiemetic drug classifications to act on different receptors will optimize the prevention or treatment of PONV.  
\- TIVA with a continuous propofol infusion is very popular in high-risk PONV patients.  
\- Risk for PONV is nine times less among patients receiving regional anesthesia than those receiving general anesthesia.  
  
**Five primary afferent pathways are involved in stimulating vomiting.**  
1) The chemoreceptor trigger zone (CTZ)  
2) The vagal mucosal pathway in the gastrointestinal system  
3) Neuronal pathways from the vestibular system  
4) Reflex afferent pathways from the cerebral cortex  
5) Midbrain afferents.  
  
**Stimulation of one of the above afferent pathways can activate the sensation of vomiting via:  
**\- Cholinergic (muscarinic) receptors  
\- Dopaminergic receptors  
\- Histaminergic receptors  
\- Serotonergic receptors  
  
**Adult risk factors for PONV:  
**\- History of motion sickness\- History of PONV\- Female gender  
\- Nonsmoker  
\- Younger age  
\- Nitrous oxide (appears to be duration dependent)  
\- Postoperative opioids  
  
**Disproven or no evidence as a risk factor for PONV in the adult patient:**  
\- BMI  
\- Anxiety  
\- Nasogastric tube  
\- Migraine headache  
  
**Surgical risk factors:**  
\- **Type of surgical procedure:** Cholecystectomy, laparoscopic and gynecological  
\- **Duration of anesthesia:** Increasing operative duration by 30 min may increase the risk of PONV by 60%.  
**  
Anesthesia-induced risk factors:**  
\- General anesthesia > regional  
\- Using volatile anesthetics  
\- Nitrous oxide (appears to be duration dependent)  
\- High doses of opioids  
  
**Apfel simplified risk score for PONV:**  
\- This score is based on four predictors: female sex, history of PONV, motion sickness, nonsmoking status, and use of postoperative opioids.  
  
**Apfel Score to predict PONV:** table.tableizer-table { font-size: 12px; border: 1px solid #CCC; font-family: Arial, Helvetica, sans-serif; } .tableizer-table td { padding: 4px; margin: 3px; border: 1px solid #CCC; } .tableizer-table th { background-color: #104E8B; color: #FFF; font-weight: bold; }

| Characteristics | Points |
| --- | --- |
| Female sex | 1 |
| History of motions sickness or PONV | 1 |
| Nonsmoker | 1 |
| Post-op opioid treatment is planned | 1 |

  
**Prediction of PONV with Apfel Score:** table.tableizer-table { font-size: 12px; border: 1px solid #CCC; font-family: Arial, Helvetica, sans-serif; } .tableizer-table td { padding: 4px; margin: 3px; border: 1px solid #CCC; } .tableizer-table th { background-color: #104E8B; color: #FFF; font-weight: bold; }

| Score | Prediction of PONV |
| --- | --- |
| 0 | 10% |
| 1 | 20% |
| 2 | 40% |
| 3 | 60% |
| 4 | 80% |

  
**Antiemetics and receptors involved:** table.tableizer-table { font-size: 12px; border: 1px solid #CCC; font-family: Arial, Helvetica, sans-serif; } .tableizer-table td { padding: 4px; margin: 3px; border: 1px solid #CCC; } .tableizer-table th { background-color: #104E8B; color: #FFF; font-weight: bold; }

| Receptors involved | Antiemetic examples |
| --- | --- |
| Serotonin 5ht3 (5-hydroxytryptamine subtype 3) antagonist | Ondansetron, Granisetron, Dolasetron,  
Ramosetron, Palonosetron and Tropisetron |
| Anticholinergic/antimuscarinics | Scopolamine transdermal |
| Histamine (H1) antagonist (first generation) | Benadryl and Phenergan |
| Dopamine (D2) antagonists | Droperidol, Haloperidol, Reglan |
| Neorokinin-1 antagonist | Aprepitant (emend) |
| Cannabinoid agonist | Marinol |
| Adjuvant-Glucocorticoid steroids | Dexamethasone |

  
**Antiemetic classifications, dosing, and timing:**  
**5HT receptor antagonists:** End of case  
**Ondansetron:** 4 mg IV at the end of the procedure (most popular)  
**Granisetron:** 0.35–3 mg IV at the end of the procedure (rare in the US)  
**Dolasetron:** 12.5 mg IV at the end of the procedure (rare in the US)  
  
**Anticholinergic:** 2 hours pre-op (before induction)  
**Scopolamine transdermal patch:** 1.5 mg  
  
**Butyrophenones:** Perioperative (usually intra or post-op)  
**Haldol:** 2 mg (used in some bariatric ERAS protocols)  
**Droperidol:** 0.625-1.25 mg IV  
  
**Antiemetic, Prokinetic:**  
**Metoclopramide (Reglan):** 10 mg IV pre-op  
Controversial due to potential side effects (Black Box warning)  
  
**Potential side effects:** Restlessness (akathisia), focal dystonia, and extrapyramidal effects.  
Not a butyrophenone  
  
**Neurokinin receptor antagonists:** 1-hour Pre-op  
**Aprepitant (emend):** 40 mg PO  
  
**First-generation antihistamines:** Perioperative (usually intra or post-op)  
**Diphenhydramine (Benadryl):** 6.25 to 12.5 mg IV  
**Promethazine (Phenergan):** 6.25-12.5 mg IV  
**Note:** These two drugs cause drowsiness and may delay emergence.  
  
**Cannabinoid (miscellaneous antiemetic):** 1-hour pre-op  
**Marinol:** 5 mg PO  
  
**Glucocorticoid steroids:** Post induction  
**Dexamethasone:** 4-8 mg IV post-induction (very popular)  
  
**Common anesthesia practices and recommendations to reduce the risk for PONV patients:**  
**Preoperative Prophylaxis:**  
**\- Marinol:** 2.5 to 5 mg PO, 30-60 minutes before induction  
**\- Scopolamine transdermal patch:** 1.5 mg patch 2 hours before induction (avoid with elderly)  
\- Adequate IV hydration  
\- Emend (Aprepitant) Less common-expensive  
\- Avoid general anesthesia that involves volatile anesthetics  
\- Avoid Nitrous Oxide  
\- Use TIVA with propofol continuous infusion  
  
**Minimize the use of intraoperative opioids:**  
Refer to the link: “Nonopioid Agents and Dosing Cheat Sheets” for more nonopioid agents and doses within this Mega App.  
  
**Common preoperative nonopioid agents to reduce perioperative opioids:**  
**Acetaminophen:** PO and cheaper than the IV form (Ofirmev)  
**COX-2 inhibitors (Celebrex):** opioid-sparing  
**Gabapentinoid:** Lyrica (pregabalin) or Neurontin (gabapentin)  
  
**Avoid neostigmine (anticholinesterases):** Consider sugammadex instead.  
Consider an OG tube to decompress the stomach.  
  
**Dexmedetomidine for PONV:**  
It has been published that dexmedetomidine has reduced the incidence of PONV like 8 mg of dexamethasone, and reduced pain in the first 24 hours after surgery.  
  
**Published dose:** 1 mcg/kg before skin incision may decrease PONV.  
**Note:** However, 1 mcg/kg is considered a high dose for dexmedetomidine, as most anesthesia providers limit the dose to 0.5 mg/kg.  
  
Antiemetic Black Box warnings: table.tableizer-table { font-size: 12px; border: 1px solid #CCC; font-family: Arial, Helvetica, sans-serif; } .tableizer-table td { padding: 4px; margin: 3px; border: 1px solid #CCC; } .tableizer-table th { background-color: #104E8B; color: #FFF; font-weight: bold; }

| Agent | Black Box Warning |
| --- | --- |
| Droperidol (Inapsine) | May cause QT prolongation.  
Avoid with congenital QT prolongation. |
| Ondansetron (Zofran): | May cause QT prolongation.  
Avoid with congenital QT prolongation. |
| Metoclopramide (Reglan) | May cause tardive dyskinesia.  
Avoid with Parkinson's |

  
  

Fourth consensus guidelines for the management of postoperative nausea and vomiting.  
Anesthesia & Analgesia _._ 2020; **131** :411–448  
Tong J. Gan, MD, MBA, MHS, FRCA, Kumar G. Belani, MBBS, MS, Sergio Bergese, MD,  
Frances Chung, MBBS, Pierre Diemunsch, MD, PhD, Ashraf S. Habib, MBBCh, MSc, MHSc, FRCA, Zhaosheng Jin, MBBS, BSc, Anthony L. Kovac, MD, Tricia A. Meyer, PharmD, MS, FASHP, FTSHP, Richard D. Urman, MD, MBA, Christian C. Apfel, MD, PhD, Sabry Ayad, MD, MBA, FASA, Linda Beagley, MS, RN, CPAN, FASPAN, Keith Candiotti, MD, Marina Englesakis, BA (Hons), MLIS, Traci L. Hedrick, MD, MSc, Peter Kranke, MD, MBA, Samuel Lee, CAA,  
Daniel Lipman, DNP, CRNA, Harold S. Minkowitz, MD, John Morton, MD, MPH, MHA,  
and Beverly K. Philip, MD  
  
Current concepts in the management of postoperative nausea and vomiting  
Anesthesiology Research and Practice 2011;2011:748031.  
S Chatterjee 1 , A Rudra, S Sengupta  
  
Postoperative nausea and vomiting: A simple yet complex problemAnesthesia Essays and Research. 2016 Sep-Dec; 10(3): 388–396.  
Safiya Imtiaz Shaikh, D. Nagarekha, Ganapati Hegade, and M. Marutheesh  
  
Prophylaxis for postoperative nausea and vomiting (PONV) in adults  
UpToDate (accessed 08/2023)  
https://tinyurl.com/bddstafw  
  
Promethazine  
DrugBank.com (accessed 08/2023)  
https://go.drugbank.com/drugs/DB01069Reglan & Tardive Dyskinesia  
Drugwatch (accessed 08/2023)  
https://tinyurl.com/47h258cc  
  
Antiemetic Histamine H1 Receptor Blockers  
StatPearls (accessed 08/2023)  
Travis S. Schaefer; Patrick M. Zito.  
https://www.ncbi.nlm.nih.gov/books/NBK533003/Nausea, emesis, and antiemetics  
The Internet Book of Critical Care (accessed 08/2023)  
Josh Farkas  
https://emcrit.org/ibcc/antiemetic/#metoclopramide